Abstract
Several novel compounds recently appeared as promising leads to develop effective drugs against the basic defect in Cystic fibrosis (CF) and the first rationale therapies for CF relying on the understanding of the basic defect started to hit the clinical setting. Most of these efforts are focused on correcting the F508del mutation (occurring in ∼90% of CF patients) which causes misfolding of the CF transmembrane conductance regulator (CFTR) protein, the intracellular retention of such abnormal conformation by the endoplasmic reticulum quality control and premature degradation, thus precluding CFTR from reaching the cell membrane where it normally functions as a cAMP-stimulated Cl- channel. Here, several rationale therapeutic strategies are briefly reviewed, namely, mutation-specific (or “CFTR-repairing”) approaches (with a particular focus on the cellular defect associated with F508del-CFTR), manipulation of other ionic (non-CFTR) conductances and gene therapy. Still more innovative strategies, such as manipulation of the proteostasis network, displacement of molecular chaperones, targeting mutant CFTR by in silico small-molecule screens and systems biology approaches are also discussed.
Keywords: Basic defect, CFTR modulator, corrector, F508del, drug discovery, cystic fibrosis, pseudomonas aeruginosa, gene mutations, ionic conductances, chaperones
Current Drug Targets
Title: Targeting CFTR: How to Treat Cystic Fibrosis by CFTR-Repairing Therapies
Volume: 12 Issue: 5
Author(s): Margarida D. Amaral
Affiliation:
Keywords: Basic defect, CFTR modulator, corrector, F508del, drug discovery, cystic fibrosis, pseudomonas aeruginosa, gene mutations, ionic conductances, chaperones
Abstract: Several novel compounds recently appeared as promising leads to develop effective drugs against the basic defect in Cystic fibrosis (CF) and the first rationale therapies for CF relying on the understanding of the basic defect started to hit the clinical setting. Most of these efforts are focused on correcting the F508del mutation (occurring in ∼90% of CF patients) which causes misfolding of the CF transmembrane conductance regulator (CFTR) protein, the intracellular retention of such abnormal conformation by the endoplasmic reticulum quality control and premature degradation, thus precluding CFTR from reaching the cell membrane where it normally functions as a cAMP-stimulated Cl- channel. Here, several rationale therapeutic strategies are briefly reviewed, namely, mutation-specific (or “CFTR-repairing”) approaches (with a particular focus on the cellular defect associated with F508del-CFTR), manipulation of other ionic (non-CFTR) conductances and gene therapy. Still more innovative strategies, such as manipulation of the proteostasis network, displacement of molecular chaperones, targeting mutant CFTR by in silico small-molecule screens and systems biology approaches are also discussed.
Export Options
About this article
Cite this article as:
D. Amaral Margarida, Targeting CFTR: How to Treat Cystic Fibrosis by CFTR-Repairing Therapies, Current Drug Targets 2011; 12 (5) . https://dx.doi.org/10.2174/138945011795378586
DOI https://dx.doi.org/10.2174/138945011795378586 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Hydroxychloroquine and Azithromycin Combination in the Management of COVID-19 Infection: Safety and Effectiveness Challenges
Current Drug Safety Iron Chelators for the Treatment of Cancer
Current Medicinal Chemistry Ziconotide: Neuronal Calcium Channel Blocker for Treating Severe Chronic Pain
Current Medicinal Chemistry A Review on Emerging Drug Targets in Treatment of Schizophrenia
Current Drug Targets Recent Advances in Sepsis Research: Novel Biomarkers and Therapeutic Targets
Current Medicinal Chemistry Neuroleptic Malignant Syndrome: A Review from a Clinically Oriented Perspective
Current Neuropharmacology Biotechnological Approaches for the Treatment of Inflammatory Diseases
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Rituximab The First Monoclonal Antibody Approved for the Treatment of Lymphoma
Current Pharmaceutical Biotechnology Discovery and Development of Antifungal Compounds
Current Medicinal Chemistry - Anti-Infective Agents Roles of Renal Proximal Tubule Transport in the Pathogenesis of Hypertension
Current Hypertension Reviews Naturally Occurring Peptides from Rana temporaria: Antimicrobial Properties and More
Current Topics in Medicinal Chemistry microRNAs: Innovative Targets for Cerebral Ischemia and Stroke
Current Drug Targets siRNA Silencing of Gene Expression in Trabecular Meshwork: RhoA siRNA Reduces IOP in Mice
Current Molecular Medicine Health Benefits of Honey: Implications for Treating Cardiovascular Diseases
Current Nutrition & Food Science Recombinant Immunotoxins for the Treatment of Chemoresistant Hematologic Malignancies
Current Pharmaceutical Design Ruthenium as an Effective Nitric Oxide Scavenger
Current Topics in Medicinal Chemistry Radiolabelled Regulatory Peptides for Imaging and Therapy
Anti-Cancer Agents in Medicinal Chemistry Microbial Biotransformation: Recent Developments on Steroid Drugs
Recent Patents on Biotechnology Immunotherapy for Food Allergies in Children
Current Pharmaceutical Design Tumor Necrosis Factor: Renaissance as a Cancer Therapeutic?
Current Cancer Drug Targets